Integrated Cancer Repository for Cancer Research
Launched by UNIVERSITY OF NEBRASKA · Dec 10, 2013
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Integrated Cancer Repository for Cancer Research (iCaRe2) is a study designed to gather important information and samples from adults who have been diagnosed with cancer, those at high risk for developing cancer, and healthy individuals for comparison. This research aims to better understand the factors that contribute to cancer development and progression. By collecting data from a wide range of participants, including those from smaller and rural hospitals, the study hopes to improve prevention, early detection, and personalized treatment strategies for various types of cancer.
To be eligible for this study, participants must be adults aged 19 or older who can speak English and give consent. They can either have a personal history of cancer, show signs that they might develop cancer, or be healthy individuals who have never had cancer. Participants in this study can expect to provide information about their health and may also give samples for research. This research is important because it allows scientists to work together to find new ways to fight cancer and improve patient care.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Diagnosis/history of cancer
- • Risk for developing cancer or suspicious clinical findings
- • No history of cancer (normal control registry)
- • Able to provide informed consent
- • 19 years of age or older
- • English or Spanish speaking individuals
- • Exclusion Criteria
- • Unable to provide informed consent because of cognitive impairment
- • Non-English or non-Spanish speaking individuals
About University Of Nebraska
The University of Nebraska is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong commitment to improving patient outcomes and fostering scientific discovery, the university collaborates with various healthcare professionals and researchers to conduct rigorous clinical studies across diverse medical fields. The institution prioritizes ethical standards and patient safety while striving to translate research findings into practical solutions that enhance medical practices and contribute to the overall well-being of the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Denver, Colorado, United States
Sioux Falls, South Dakota, United States
Tallahassee, Florida, United States
Aurora, Illinois, United States
Davenport, Iowa, United States
Yankton, South Dakota, United States
New Orleans, Louisiana, United States
Omaha, Nebraska, United States
Omaha, Nebraska, United States
Rutland, Vermont, United States
Ann Arbor, Michigan, United States
Kansas City, Missouri, United States
North Platte, Nebraska, United States
Daytona Beach, Florida, United States
Moline, Illinois, United States
Holyoke, Massachusetts, United States
Randallstown, Maryland, United States
Parker, Colorado, United States
Canton, Ohio, United States
Fredericksburg, Virginia, United States
Yankton, South Dakota, United States
Indianapolis, Indiana, United States
Fayetteville, North Carolina, United States
Colorado Springs, Colorado, United States
Yorkville, Illinois, United States
Spencer, Iowa, United States
Oshkosh, Wisconsin, United States
Deland, Florida, United States
Orange City, Florida, United States
Palm Coast, Florida, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Council Bluffs, Iowa, United States
Waterloo, Iowa, United States
Overland Park, Kansas, United States
Westminster, Maryland, United States
Joplin, Missouri, United States
Kansas City, Missouri, United States
Kansas City, Missouri, United States
Liberty, Missouri, United States
Hastings, Nebraska, United States
Norfolk, Nebraska, United States
Scottsbluff, Nebraska, United States
Glens Falls, New York, United States
Minot, North Dakota, United States
Aberdeen, South Dakota, United States
Mitchell, South Dakota, United States
Brookfield, Wisconsin, United States
Franklin, Wisconsin, United States
Racine, Wisconsin, United States
Wauwatosa, Wisconsin, United States
Lakewood, Colorado, United States
Fort Wayne, Indiana, United States
Sioux Falls, South Dakota, United States
Aitkin, Minnesota, United States
Milwaukee, Wisconsin, United States
Sioux Falls, South Dakota, United States
Mequon, Wisconsin, United States
Durango, Colorado, United States
Littleton, Colorado, United States
Longmont, Colorado, United States
Louisville, Colorado, United States
Pueblo, Colorado, United States
Westminster, Colorado, United States
Kokomo, Indiana, United States
Portland, Maine, United States
Brainerd, Minnesota, United States
Duluth, Minnesota, United States
Duluth, Minnesota, United States
Fergus Falls, Minnesota, United States
Marshall, Minnesota, United States
Saint Joseph, Missouri, United States
Bozeman, Montana, United States
Kalispell, Montana, United States
Missoula, Montana, United States
O'neill, Nebraska, United States
Omaha, Nebraska, United States
Utica, New York, United States
Fargo, North Dakota, United States
Alliance, Ohio, United States
Pittsburgh, Pennsylvania, United States
Yankton, South Dakota, United States
Appleton, Wisconsin, United States
Green Bay, Wisconsin, United States
Kansas City, Missouri, United States
Kansas City, Missouri, United States
Liberty, Missouri, United States
Hastings, Nebraska, United States
Utica, New York, United States
Franklin, Wisconsin, United States
Racine, Wisconsin, United States
Wauwatosa, Wisconsin, United States
Bristol, Connecticut, United States
Greenwood Village, Colorado, United States
Patients applied
Trial Officials
Quan Ly, MD
Principal Investigator
University of Nebraska
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials